Table 2 Study Design 2 - Budesonide/formoterol maintenance and reliever therapy vs higher fixed dose budesonide/formoterol maintenance therapy
From: Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma
Kuna et al.13 | Maintenance and Reliever Therapy | Higher Fixed Dose Maintenance Therapy | Relative Risk (95% CI) | P |
|---|---|---|---|---|
Risk of severe exacerbations: | ||||
 (No. participants with at least one severe exacerbation/ No. participants randomised to treatment regimen) | 94/1107 (8.5%) | 126/1105 (11.4%) | 0.74 (0.58 to 0.96) | 0.02 |
Mean dose: | Â | Â | Ratio | Â |
 Budesonide (μg/day) | 483 (320 maintenance; 163 reliever) | 640 | 0.75 |  |
 Formoterol (μg/day) | 13.6 (9 maintenance; 4.6 reliever) | 18 | 0.75 |  |
| Â | Â | Â | Difference (95% CI) | Â |
FEV1 (L, mean (SD)) | 2.69 | 2.66 | 0.01 (−0.03 to 0.04) | – |
Asthma symptoms score (mean total score) | 1.06 | 1.07 | 0.00 (−0.07 to 0.06) | – |